Altered regulation of insulin-like growth factor binding protein-I in patients with polycystic ovary syndrome

Enrico Carmina, Frank Z. Stanczyk, Randy S. Morris, Phillip Lee, Gopal Savjani, Rogerio A. Lobo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective:Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women. Methods: We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 ± 1 and 22 ± 1 years, respectively). All subjects were studied after an overnight fast between days 5-8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of a euglycemic clamp, and, in a subsequent cycle, the administration of a long-acting somatostatin analogue (octreotide, 100 μg) given subcutaneously. Blood samples were collected before treatment, every 15 minutes for 6 hours after insulin, and every 30 minutes for 3 hours after octreotide administration. Serum levels of IGF-I, IGFBP-1, IGFBP-3, and insulin were measured by specific immunoassays. Results: Compared with the controls, patients with PCOS had significantly higher insulin levels, similar IGF-I and IGFBP-3 levels, and significantly lower IGFBP-1. Insulin did not change serum IGF-I levels in either group, although a significant decrease in IGFBP-1 levels occurred in normal women but not in patients with PCOS. Octreotide treatment also did not change serum IGF-I levels in either group, but serum insulin levels decreased significantly and IGFBP-1 levels increased significantly in both groups; this response was significantly greater in controls. Conclusion: Our data are compatible with the notion that regulation of IGFBP-1 is altered in women with PCOS and that several factors may be involved.

Original languageEnglish (US)
Pages (from-to)743-747
Number of pages5
JournalJournal of the Society for Gynecologic Investigation
Volume2
Issue number6
StatePublished - Nov 1995
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Proteins
Polycystic Ovary Syndrome
Insulin-Like Growth Factor I
Insulin
Octreotide
Insulin-Like Growth Factor Binding Protein 3
Serum
Glucose Clamp Technique
Menstruation
Progestins
Somatostatin
Immunoassay
Blood Proteins
Carrier Proteins
Maintenance
Therapeutics

Keywords

  • Insulin-like growth factor binding-protein 1
  • polycystic ovary syndrome

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Developmental Biology

Cite this

Altered regulation of insulin-like growth factor binding protein-I in patients with polycystic ovary syndrome. / Carmina, Enrico; Stanczyk, Frank Z.; Morris, Randy S.; Lee, Phillip; Savjani, Gopal; Lobo, Rogerio A.

In: Journal of the Society for Gynecologic Investigation, Vol. 2, No. 6, 11.1995, p. 743-747.

Research output: Contribution to journalArticle

Carmina, Enrico ; Stanczyk, Frank Z. ; Morris, Randy S. ; Lee, Phillip ; Savjani, Gopal ; Lobo, Rogerio A. / Altered regulation of insulin-like growth factor binding protein-I in patients with polycystic ovary syndrome. In: Journal of the Society for Gynecologic Investigation. 1995 ; Vol. 2, No. 6. pp. 743-747.
@article{7def974d86de40e18f97ae17500f94d3,
title = "Altered regulation of insulin-like growth factor binding protein-I in patients with polycystic ovary syndrome",
abstract = "Objective:Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women. Methods: We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 ± 1 and 22 ± 1 years, respectively). All subjects were studied after an overnight fast between days 5-8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of a euglycemic clamp, and, in a subsequent cycle, the administration of a long-acting somatostatin analogue (octreotide, 100 μg) given subcutaneously. Blood samples were collected before treatment, every 15 minutes for 6 hours after insulin, and every 30 minutes for 3 hours after octreotide administration. Serum levels of IGF-I, IGFBP-1, IGFBP-3, and insulin were measured by specific immunoassays. Results: Compared with the controls, patients with PCOS had significantly higher insulin levels, similar IGF-I and IGFBP-3 levels, and significantly lower IGFBP-1. Insulin did not change serum IGF-I levels in either group, although a significant decrease in IGFBP-1 levels occurred in normal women but not in patients with PCOS. Octreotide treatment also did not change serum IGF-I levels in either group, but serum insulin levels decreased significantly and IGFBP-1 levels increased significantly in both groups; this response was significantly greater in controls. Conclusion: Our data are compatible with the notion that regulation of IGFBP-1 is altered in women with PCOS and that several factors may be involved.",
keywords = "Insulin-like growth factor binding-protein 1, polycystic ovary syndrome",
author = "Enrico Carmina and Stanczyk, {Frank Z.} and Morris, {Randy S.} and Phillip Lee and Gopal Savjani and Lobo, {Rogerio A.}",
year = "1995",
month = "11",
language = "English (US)",
volume = "2",
pages = "743--747",
journal = "Reproductive Sciences",
issn = "1933-7191",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Altered regulation of insulin-like growth factor binding protein-I in patients with polycystic ovary syndrome

AU - Carmina, Enrico

AU - Stanczyk, Frank Z.

AU - Morris, Randy S.

AU - Lee, Phillip

AU - Savjani, Gopal

AU - Lobo, Rogerio A.

PY - 1995/11

Y1 - 1995/11

N2 - Objective:Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women. Methods: We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 ± 1 and 22 ± 1 years, respectively). All subjects were studied after an overnight fast between days 5-8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of a euglycemic clamp, and, in a subsequent cycle, the administration of a long-acting somatostatin analogue (octreotide, 100 μg) given subcutaneously. Blood samples were collected before treatment, every 15 minutes for 6 hours after insulin, and every 30 minutes for 3 hours after octreotide administration. Serum levels of IGF-I, IGFBP-1, IGFBP-3, and insulin were measured by specific immunoassays. Results: Compared with the controls, patients with PCOS had significantly higher insulin levels, similar IGF-I and IGFBP-3 levels, and significantly lower IGFBP-1. Insulin did not change serum IGF-I levels in either group, although a significant decrease in IGFBP-1 levels occurred in normal women but not in patients with PCOS. Octreotide treatment also did not change serum IGF-I levels in either group, but serum insulin levels decreased significantly and IGFBP-1 levels increased significantly in both groups; this response was significantly greater in controls. Conclusion: Our data are compatible with the notion that regulation of IGFBP-1 is altered in women with PCOS and that several factors may be involved.

AB - Objective:Insulin-like growth factor (IGF-I) action is influenced by circulating as well as tissue levels of its binding proteins. Because serum IGF binding protein-1 (IGFBP-1) levels have been found to be decreased in patients with polycystic ovary syndrome (PCOS), we tested the hypothesis that regulation of IGFBP-1 secretion may be different in patients with PCOS compared with normal women. Methods: We studied 15 normal ovulatory women and 15 women with PCOS of similar age (21 ± 1 and 22 ± 1 years, respectively). All subjects were studied after an overnight fast between days 5-8 after spontaneous or progestin-induced menses. Perturbations included the administration of insulin intravenously, maintenance of a euglycemic clamp, and, in a subsequent cycle, the administration of a long-acting somatostatin analogue (octreotide, 100 μg) given subcutaneously. Blood samples were collected before treatment, every 15 minutes for 6 hours after insulin, and every 30 minutes for 3 hours after octreotide administration. Serum levels of IGF-I, IGFBP-1, IGFBP-3, and insulin were measured by specific immunoassays. Results: Compared with the controls, patients with PCOS had significantly higher insulin levels, similar IGF-I and IGFBP-3 levels, and significantly lower IGFBP-1. Insulin did not change serum IGF-I levels in either group, although a significant decrease in IGFBP-1 levels occurred in normal women but not in patients with PCOS. Octreotide treatment also did not change serum IGF-I levels in either group, but serum insulin levels decreased significantly and IGFBP-1 levels increased significantly in both groups; this response was significantly greater in controls. Conclusion: Our data are compatible with the notion that regulation of IGFBP-1 is altered in women with PCOS and that several factors may be involved.

KW - Insulin-like growth factor binding-protein 1

KW - polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=0028875183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028875183&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 743

EP - 747

JO - Reproductive Sciences

JF - Reproductive Sciences

SN - 1933-7191

IS - 6

ER -